investing

Gilead Sciences' (GILD) Remdesivir Sparks Market Hope With Trial Success

Gilead's COVID-19 treatment shows efficacy in Phase 3 trial, NIAID study

Gilead Sciences (GILD, $78.67) reprised its goal as one of Wall Street's most-watched health care stocks on Wednesday after announcing positive results from trials for its COVID-19 treatment remdesivir.

Gilead announced that its COVID-19 treatment remdesivir met its primary endpoint in a National Institute of Allergy and Infectious Diseases (NIAID) clinical study. It also provided encouraging data from an open-label Phase 3 trial.

The Phase 3 trial focused on severely ill patients and found similar results for those who took five- or 10-day dosing durations, with "more than half of patients in both treatment groups (being) discharged from the hospital by Day 14."

"The study demonstrates the potential for some patients to be treated with a 5-day regimen, which could significantly expand the number of patients who could be treated with our current supply of remdesivir," Gilead Chief Medical Officer Merdad Parsey said in a release. "This is particularly important in the setting of a pandemic, to help hospitals and healthcare workers treat more patients in urgent need of care."

Later Wednesday, the U.S. Food and Drug Administration said it was in "sustained and ongoing" discussions with the drugmaker over making its COVID-19 treatment available "as quickly as possible, as appropriate." The New York Times reported that a senior administration official said remdesivir could get FDA authorization for emergency use as soon as today.

GILD stock, which has climbed 21% through April 28, versus an 11% loss for the S&P 500, was up 9% in premarket action after a trading halt for the pending news. The company's stock has climbed in 2020 amid hopes that remdesivir – which Gilead introduced years ago as a general antiviral and was previously tested as an Ebola treatment – would prove effective against the COVID-19 coronavirus.

However, the drug is of interest to more than just GILD shareholders.

Because of its potential, the broader stock market has occasionally ebbed and flowed on any shreds of information about remdesivir's performance in clinical trials. Indeed, stock-market index futures surged higher ahead of Wednesday's open following Gilead's reports.

Remdesivir was touted early as a possible game-changer in the world's battle against COVID-19. "There's only one drug right now that we think may have real efficacy. And that's remdesivir," Bruce Aylward, an international leader of the World Health Organization's joint mission to China, said Feb. 24.

The market jumped April 16 amid a STAT News report claiming success against COVID-19 in a Chicago hospital. However, stocks broadly receded April 23 after the WHO accidentally published draft documents outlining a disappointing Chinese trial – documents that Gilead said included "inappropriate characterizations of the study."

Most Popular

Top Bear Market Tips from 10 Financial Advisers
investing

Top Bear Market Tips from 10 Financial Advisers

When a bull market turns into a bear market, it can be hard to know what to do. Take comfort in the guidance of 10 financial professionals.
June 30, 2022
Your Guide to Roth Conversions
Special Report
Tax Breaks

Your Guide to Roth Conversions

A Kiplinger Special Report
February 25, 2021
The 15 Best Stocks for the Rest of 2022
stocks to buy

The 15 Best Stocks for the Rest of 2022

The lesson of the past two years: Be ready for anything. Our 15 best stocks to buy for the rest of 2022 reflect several possible outcomes for the seco…
June 21, 2022

Recommended

Is the Stock Market Closed for the Fourth of July in 2022?
Markets

Is the Stock Market Closed for the Fourth of July in 2022?

Independence Day falls on a Monday in 2022, so the bond and stock markets will enjoy a long holiday weekend. Here's a look at the markets' holiday hou…
July 1, 2022
Top Bear Market Tips from 10 Financial Advisers
investing

Top Bear Market Tips from 10 Financial Advisers

When a bull market turns into a bear market, it can be hard to know what to do. Take comfort in the guidance of 10 financial professionals.
June 30, 2022
Move Over ETFs: Direct Indexing Is an Investment Strategy Worth Paying Attention to
investing

Move Over ETFs: Direct Indexing Is an Investment Strategy Worth Paying Attention to

More flexibility, more control, the potential for higher returns and tax-reducing strategies: With pros like that, could direct indexing be right for …
June 25, 2022
Smart Investing in a Bear Market
investing

Smart Investing in a Bear Market

Here's how to make the most of today’s dicey market.
June 22, 2022